Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more
Rhythm Pharmaceuticals Inc (RYTM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.183x
Based on the latest financial reports, Rhythm Pharmaceuticals Inc (RYTM) has a cash flow conversion efficiency ratio of -0.183x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.39 Million) by net assets ($139.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rhythm Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rhythm Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rhythm Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rhythm Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AAON INC. DL-004
F:AAO
|
N/A |
|
SHIMAMURA Co. Ltd
PINK:SHAOF
|
0.015x |
|
Posco Chemical Co Ltd
KO:003670
|
-0.026x |
|
Tripod Technology Corp
TW:3044
|
0.058x |
|
Boot Barn Holdings Inc
NYSE:BOOT
|
0.163x |
|
NewMarket Corporation
NYSE:NEU
|
0.320x |
|
Terawulf Inc
NASDAQ:WULF
|
-0.148x |
|
China Railway Group Limited
PINK:CRWOF
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rhythm Pharmaceuticals Inc from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $139.07 Million | $-115.67 Million | -0.832x | -20.19% |
| 2024-12-31 | $164.55 Million | $-113.88 Million | -0.692x | +13.71% |
| 2023-12-31 | $169.76 Million | $-136.16 Million | -0.802x | -22.21% |
| 2022-12-31 | $264.26 Million | $-173.43 Million | -0.656x | -27.72% |
| 2021-12-31 | $284.15 Million | $-146.00 Million | -0.514x | +29.85% |
| 2020-12-31 | $166.53 Million | $-121.98 Million | -0.732x | -67.69% |
| 2019-12-31 | $281.02 Million | $-122.75 Million | -0.437x | -73.34% |
| 2018-12-31 | $246.26 Million | $-62.06 Million | -0.252x | -23.85% |
| 2017-12-31 | $144.79 Million | $-29.46 Million | -0.203x | +93.61% |
| 2016-12-31 | $7.30 Million | $-23.22 Million | -3.182x | -1359.47% |
| 2015-12-31 | $32.00 Million | $-6.98 Million | -0.218x | -101.04% |
| 2014-12-31 | $-358.00K | $-7.51 Million | 20.972x | +6190.74% |
| 2013-12-31 | $-57.46 Million | $-19.16 Million | 0.333x | -32.16% |
| 2012-12-31 | $-36.28 Million | $-17.83 Million | 0.491x | -- |